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Abstract
Objective: To determine if the WATCHMAN device is as efficacious as warfarin for stroke
prevention in patients with non-valvular atrial fibrillation (NVAF) using a systematic review.
Methods: Pubmed and Google Scholar databases were used to evaluate clinical trials using the
search terms atrial fibrillation, watchman, warfarin, and stroke prevention. Results: Three
studies met inclusion criteria, with 2 being randomized control trials (RCT), and 1 being a
prospective cohort study. Reddy et al found that after 3.8 years of follow-up, patients with
percutaneous closure of Left atrial appendage (LAA) met criteria for both non-inferiority and
superiority, compared with warfarin for preventing combined outcome for stroke. Holmes et al
showed at 18 months follow-up that the WATCHMAN device and warfarin therapy groups had
similar efficacy endpoints. The device group was shown to be non-inferior to the control group
in late-ischemic stroke 7 days post procedure, and was found to be equally as safe. Boresma et al
showed that at the 1-year follow-up there was a lower risk of stroke in the device group, and that
the earliest discontinuation of anticoagulant therapy had the lowest risk of bleeding. Conclusion:
This systematic review shows evidence that the WATCHMAN implantable LAA device may be
a suitable alternative to prevent thromboembolism in patients with NVAF who may have a
contraindication for long-term warfarin or anticoagulation use. Due to the novel technology of
the WATCHMAN implant, more studies should be completed to determine its long-term
efficacy and adverse events.
Introduction:
Stroke is a leading cause of long-term disability in the United States. Stroke also accounts for
approximately 140,000 deaths every year and it is the fifth leading cause of death among
Americans, according to the Center for Disease Control 1. In the United States someone has a
stroke every 40 seconds, and someone dies of a stroke every 4 minutes1. A major risk factor for
ischemic stroke is atrial fibrillation (AFib). AFib increases the risk of stroke four to five-fold
compared to those without AFib2. Due to the irregular contraction of the atria, blood clots can
form and embolize to the brain. Among various treatments for AFib, such as the WATCHMAN
procedure, anticoagulants have been the mainstay of treatment in prevention of clot formation
leading to stroke.
Warfarin (Coumadin) was the only known anticoagulant for years, reducing risk of stroke by 5070%3. Warfarin affects the extrinsic pathway, blocking the formation of vitamin K dependent
factors3. With this, there is an increased risk of bleeding while on warfarin. To monitor blood
levels, an international normalized ratio (INR) is performed every 4-6 weeks to maintain a
therapeutic range4. A diet high in leafy green vegetables, vitamin K supplements, various
medications such as antibiotics and non-steroidal anti-inflammatory drugs, and alcohol can all
affect the levels of warfarin causing drastic changes in the INR. The dangerous risk of bleeding
as well as inconveniences related to warfarin use in day-to-day life has led to further
development of new technologies to reduce the risk of stroke.
A new treatment that has been FDA approved for the reduction of strokes in patients with NVAF
is the WATCHMAN implant. It is a device that is implanted into the left atrial appendage, which
is where more than 90% of stroke forming clots form5. This filter prevents clots from forming in
the LAA by allowing heart tissue growth over the implant to permanently seal in order to prevent
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embolisms to the brain5. Three studies looking at the efficacy of the WATCHMAN device are
reviewed here.
PICO:
Population: Adults with non-valvular atrial fibrillation
Intervention: WATCHMAN device
Control: Warfarin as anticoagulant therapy
Outcome: preventing blood clots that lead to stroke
Clinical Question:
Is the WATCHMAN device as efficacious as warfarin at reducing the risk of stroke in patients
with non-valvular AFib?
Methods
An initial Pubmed and Google Scholar search was performed in September 2019 using the
following key search terms: WATCHMAN, warfarin, atrial fibrillation, stroke, prevention, and
comparison which yielded 47 articles in PubMed and 49 in Google Scholar. 83 articles were
reviewed once the duplicates were removed, of which 73 articles were then removed because
they were systematic reviews, comparing different NVAF treatment procedures, or various
closure techniques of LAA procedure. The 10 remaining articles were reviewed, of which 7 were
excluded due to not being full-text articles, were meta-analysis, or study end-points different
than that of our objective.
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Figure 1. PRISMA flow diagram
Study 1: Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a
randomized clinical trial. Reddy et. al. PROTECT AF
Study objective: To determine whether a local strategy of mechanical left atrial appendage
(LAA) closure was noninferior to warfarin.
Study design: The study (PROTECT AF) was a multicenter, randomized (2:1) unblinded,
Bayesian- designed study conducted at 59 hospitals with 707 patients with nonvalvular AF and at
least one other stroke risk factor (CHADS2 >1).6 Enrollment occurred between February 2005
and June 2008 and included a 4 year follow up through October 2012. Noninferiority required a
posterior probability greater than 97.5% and a superior probability of 95% or greater; the
noninferiority margin was a rate ratio of 2.0 comparing event rates between treatment groups.
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Table 1: Inclusion and Exclusion Criteria for study participants
Inclusion criteria
1. 18 years of age or older
2. Paroxysmal, persistent, or permanent
nonvalvular AF
3. 1 or more CHADS2 risk factors (age >75
years, hypertension, diabetes, heart failure
or left ventricular systolic dysfunction,
prior transient ischemic attack (TIA) or
stroke)
4. Eligible for long term anticoagulation for
warfarin

Exclusion criteria
1. Patent foramen ovale with atrial
septal aneurysm
2. Atrial septal defect, mechanical
valve prosthesis, LV ejection
fraction less than 30%, mobile
aortic atheroma, and symptomatic
carotid disease.

Results
The study included 707 patients, 463 of which were randomized to the device group and 244 to
warfarin. There were 39 primary efficacy events (stroke, systemic embolization, and
cardiovascular or unexplained death) among 463 device patients (8.4%, 2.3 events per 100
patient-years, 95% credible interval 1.7-3.2) vs 34 events among 244 warfarin patients (13.9%,
3.8 events per 100 patient-years, 95% credible interval, 2.5- 4.9) (RR, 0.60 favoring device; 95%
credible interval, 0.41- 1.05), meeting criteria for both noninferiority (posterior probability,
>99.9%) and superiority (posterior probability, 96.0). The ischemic stroke rate in the device
group (1.4%/year, 24/463 patients) was not significantly greater than in the warfarin group
(1.1%/year, 10/244 patients, P = .49). Fewer hemorrhagic strokes occurred in the device group
(3/463 patients, 0.6%) than in the warfarin group (10/244 patients, 4.0%). In addition, fewer
cardiovascular deaths occurred in the device group (17/463 patients, 3.7%) than in the warfarin
group (22/244 patients, 9.0%).
Critique:
Strengths of this study include the relatively long follow up of 3.8 years and a relatively large
sample size of 707 patients. In addition, the majority of randomized patients received the
intended therapy, with 99% of patients in the warfarin group receiving the anticoagulant.
Adherence with therapy (the time in therapeutic range) was high compared to other studies at
70% for the warfarin group. In patients randomized to receive the device, 88% were successful
in implantation. Weaknesses of the study include patients and physicians not being blinded in
this study, which may contribute to treatment bias among the two groups. The safety endpoint
required unblinding for assessment of procedure relationship, as well as assessment for potential
thrombus on the device in stroke events. The study also reflected a predominantly male
population (70.4% in the device group vs. 70.1% in the warfarin group) and a predominantly
causasian population (91.8% in device group vs. 91% in the warfarin group). In addition, patients
receiving the LAA device had to adhere to 6 months of anticoagulation or antithrombotic
intervention (or both) to protect patients from defined primary efficacy endpoints. This study did

6
ISHERWOOD AND PARRISH

not address patients with absolute contraindications to warfarin unable to tolerate this initial
anticoagulation transition.
Study 2. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure
device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.
Holmes, et al
Objective: To assess the safety and efficacy of LAA occlusion for stroke prevention in patients
with NVAF compared with long-term warfarin therapy.
Design: The PREVAIL trial was a multicentered, randomized study that included 50 sites in the
United States. There was a total of 475 patients enrolled with NVAF and a CHADS2 score of >
2, or a score of 1 plus another risk factor (Table 2) to undergo a LAA occlusion with the
WATCHMAN procedure and discontinuation of warfarin, or either to receive chronic warfarin
treatment. This study has three coprimary endpoints: 1) primary efficacy including a composite
of hemorrhagic or ischemic stroke, SE (systemic embolism), and cardiovascular/unexplained
death, 2) late-ischemic efficacy, a composite of ischemic stroke or SE, excluding the first 7 days
after randomization, 3) a coprimary endpoint being early safety, a composite of all-cause death,
ischemic stroke, SE, or device-/procedure-related events requiring open cardiovascular surgery
or major endovascular intervention between randomization and within 7 days of the procedure or
during hospitalization.
Table 2. Inclusion and exclusion criteria for participants in the PREVAIL trial
Inclusion Criteria
1. CHADS2 score >2
2. CHADS2 score of 1 if:
• Female >75 years of age
• Baseline ejection fraction
>30%, but < 35%
• Age 65-74 years with
diabetes or
coronary artery disease
• Age >65 years with CHF

Exclusion Criteria
1. Requirement for long-term anticoagulation
therapy for reasons other than AF
2. Contraindication to warfarin or aspirin
3. Previous stroke/transient ischemic attack
within 90 days of enrollment
4. Symptomatic carotid disease
5. A patent foramen ovale or atrial septal
defect requiring treatment
6. Patients in whom clopidogrel therapy was
indicated

Results: 269 patients were randomized to the device group, and 138 to the control group. The
LAA occlusive device was successfully implanted in 95.1% of patients in which it was
attempted, with 4 patients in which the implant was not attempted even though they were
assigned the device group due to not stopping anticoagulation therapy, a new LAA thrombus
detected, and LAA size and shape were not optimal for the device. All patients had a 6 month
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minimum follow-up in which 92.2%, 98.3%, and 99.3% of patients were able to discontinue
their warfarin after 45 days, 6 months, and 12 months, respectively.
The primary endpoints of efficacy at 18 months were similarly low in both the device
(0.064) and the control group (0.063), with one stroke/SE occurring with warfarin therapy. The
second endpoint of late-ischemic primary efficacy for the rate of stroke or SE > 7 days after
randomization for the device group (0.0253), and control group (0.0200) had a 95% CI,
achieving noninferiority of the device group was shown compared to the control group. The last
endpoint of early safety was only evaluated in the device group, and was successful if the
percentage of patients experiencing one of the SE was statistically less than the performance goal
of 2.67% with an upper bound of the 1-sided 95% CI. Only 6 events occurred in the 269 patients
with the LAA device demonstrating 2.2% experienced an event, and the 1-sided upper bound
was 2.652% which successfully achieving the endpoint. This study supports that the
WATCHMAN device remains a reasonable, safe, and efficacious alternative to chronic longterm warfarin therapy for prevention of stroke in patients with NVAF.

Figure 1. Medication regimen for LAA occlusion

Critique: This PREVAIL trial adds new information to supplement the previous PROTECT AF
trial. The first primary endpoint of this study showed similar absolute event rates which did not
demonstrate that LAA occlusion is noninferior to warfarin, which is possibly due to the lowerthan-expected number of events that occurred. This is mainly due to the control group which was
found to be an “unexpected, overperforming group” which is likely due to the time-intherapeutic range of 68%, which is known to be higher than similar study designs. This study did
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not include patients whom anticoagulation is contraindicated in, contributing to the lack of data
in this population.
Study 3. Evaluating Real-World Clinical Outcomes in Atrial Fibrillation Patients Receiving the
WATCHMAN Left Atrial Appendage Closure Technology. Final 2-Year Outcome Data of the
EWOLUTION Trial Focusing on History of Stroke and Hemorrhage. Boresma, et al.
Objective: To obtain data on the overall safety, efficacy, procedural success, complications, and
long-term patient outcomes of the WATCHMAN device including subgroups at high risk of
stroke and bleeding, including patients with prior ischemic and hemorrhagic stroke and those
with prior major bleeding.
Study Design: This study is a multicenter, prospective, non-randomized cohort study. The study
began in October 2013 and was completed in May 2015, enrolling patients if they were eligible
to receive the WATCHMAN device according to the appropriate guidelines, not participating in
another trial, were not pregnant, and were able to provide informed consent. Follow-up included
a clinic visit between 1-3 months post-implant, LAA imaging, and annual follow-up visits. This
study included documentation of serious adverse events including all-cause death, strokes, TIA,
SE, perforation, tamponade, neurological events, thrombosis, and bleeding that occurred within
seven days of the implant. Study sites received on-site monitoring ranging from 2-5 times
depending on the number of patients and compliance review.
Results: A total of 1,020 patients received the WATCHMAN implant from 47 centers in 13
countries. Of the implanting physicians, 78% had <2 years of experience with the device and
performed 75% of the study participants procedures. No irregularities or discrepancies were
detected between study sites using transesophageal echocardiography (TEE) findings and first
follow up visits. At the 2-year follow-up 161 patients had died, with non-cardiovascular causes
being the most common (75), cardiovascular causes (46), bleeding (10), and unknown causes
(30). Out of the 1% bleeding as cause of death, 6 were gastrointestinal, and 4 were cerebral. Of
the cerebral bleeds, 1 was on dual antiplatelet therapy (DAPT), 1 on single antiplatelet therapy
(SAPT), 1 on warfarin, and 1 using no anticoagulation.
At hospital discharge 16% of patients were using warfarin, 11% using a novel anticoagulant
anti-coagulant (NOAC), 60% a DAPT, 58% on SAPT, and 6% on no anticoagulation. At the 2
year follow up, 8% of active patients were still on a NOAC, 7% were on DAPT, 71% were on
SAPT, while 14% were not using any anticoagulant. The conversion time to just SAPT or no
anticoagulation was 46% at 6 months, 75% at 1 year, and 95% at 2 years.
Most patients were placed on a type of anticoagulant directly after the procedure to prevent a
device-related thrombus (DRT). Out of 835 patients with follow-up imaging, 34 patients had a
DRT with 31 of them found within the first 90 days post-procedure, with the majority of clots
being non-mobile. There was no statistical significance found between the type of anticoagulant
used; but the patients on warfarin, NOAC, or DAPT were found to have the non-mobile clots.
The mobile type was seen in all patients except for patients on warfarin. In 21 patients who
experience a stroke during the 2-year period with LAA imaging performed, only 1 DRT was
found.
At the 2-year follow-up 47 patients were found to have experienced major non-procedural
bleeding. These patients were categorized by discontinuing DAPT <105 days, and those that
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discontinued >105 days. The lowest rates of bleeding were seen in the patients with earliest
discontinuation, although not found to be statistically significant. Ischemic stroke risk was
7.2/100 patient-years with a composite risk of 10.2/100 patient-years, and an observed stroke rate
of 1.3/100 patient-years. When this cohort was divided into low risk (n=118) and high risk
(n=902) for stroke, no ischemic stroke/TIA/SE was observed in those with a CHADS2 score <3.
After 1-year follow-up there was lower overall stroke, TIA, and SE. The discontinuation of
DAPT and NOAC therapy in patients at 2 years showed a 46% lower major bleeding risk
compared to the control group. In summary, the WATCHMAN LAA is a very effective and safe
alternative in preventing thrombo-embolitic events in patients with NVAF with high risk of
stroke and bleeding.
Critique: EWOLUTION is the largest prospective study on the WATCHMAN device reporting
on 2-year follow up outcomes. This study is not as strong as the previous studies due to being a
prospective cohort study rather than an RCT directly comparing WATCHMAN to warfarin use.
The study utilized center-dependent data completeness, imaging, and follow-up being the
responsibility of local investigators. This study also had a continuation of some form of NOAC
in most patients which could contribute to the additional stroke/TIA/SE prevention. The study
failed to mention the specific SAPT, DOAC, or NOAC therapies. It was mentioned that
continuing use of oral anticoagulants along with the device may also contribute to further stroke
prevention.
Discussion:
This review focused on the use of the WATCHMAN device as an alternative to warfarin
therapy for reducing the risk of stroke in patients with nonvalvular AFib. The PROTECT-AF and
PREVAIL studies were both unmasked randomized control trials, while the EWOLUTION study
was a prospective, non-randomized cohort study. The PROTECT-AF and PREVAIL studies had
similar inclusion criteria of CHADS2 score >1.6,7 The EWOLUTION study had a vast majority
of patients with much higher CHADS2 score> 4 (73.1%).8 The PREVAIL study had a primary
efficacy endpoint of 0.064 for the device group vs. 0.063 for the control group, yielding a mean
18-month rate ratio of 1.07 (95% CrI: 0.57 to 1.89)7. The upper bound of 1.89 was not lower
than the prespecified noninferiority margin of 1.75 predefined in the statistical analysis plan,
therefore, statistical noninferiority was not achieved. However, the rate of stroke or SE >7 day
after randomization was 0.0253 for the device group and 0.0200 for the control group with an
18-month risk difference 0.00533 (95% CrI- 0.0190 to 0.0273). Since the 95% CrI of the risk
difference was < 0.0275, noninferiority was achieved.7
The PROTECT AF study had a primary efficacy endpoint (which included stroke, systemic
embolism, or cardiovascular death and unexplained death) of 39 events among 463 device
patients (2.3 events per 100 patient years) compared to 34 events among 244 warfarin patients
(3.8 events per 100 patient years). This met criteria for both noninferiority (posterior probability,
>99%) and superiority (posterior probability, 96%)6.
The EWOLUTION study had a historical ischemic stroke risk of 7.2/100 patient years and
showed a composite risk of ischemic stroke/TIA/SE of 10.1/100 patient-years. The observed
stroke rate was 1.3/100 patient-years, conferring a reduction of 83% from what was expected.
The combined endpoint of ischemic TIA/SE, found the observed rate at 2.0/100 patient-years,
conferring a risk reduction of 80%.8
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Each of the studies varied in their strengths and weaknesses due to sample size, length of
study, and their endpoints. The EWOLUTION study had the largest population of patients with
1,020 participants receiving the WATCHMAN device, whereas the PROTECT AF had 463
patients receiving WATCHMAN, while the PREVAIL study had the least amount receiving the
WATCHMAN at 269 6,7,8. In addition, all 3 studies were of varying duration, with the PREVAIL
study being 18 months, compared to EWOLUTION being 2 years, and the PROTECT AF study
had a duration of 4 years. The variability in duration of the studies may have affected the
outcomes, especially when reviewing a serious adverse event such as stroke, TIA or systemic
embolism. The major findings of the PREVAIL trial were that LAA closure with the
WATCHMAN was not noninferior to warfarin for primary efficacy composite endpoint of allcause stroke, SE, cardiovascular, or unexplained death, although the event rates for warfarin
were significantly lower than expected, which affected the ability of the study to establish
noninferiority.7 The PROTECT-AF study found that the WATCHMAN device met criteria for
both noninferiority and superiority, compared to warfarin therapy, for preventing the combined
outcome of stroke, systemic embolism, and cardiovascular death, while also being superior for
cardiovascular mortality and all-cause mortality.6
The EWOLUTION study had more female participants (40.1%) in the device groups
compared to PROTECT AF and PREVAIL studies (29.6% and 32.3%respectively).The study
found that the WATCHMAN device had consistently low rates of stroke and nonprocedural
bleeding, however most were contraindicated to oral anticoagulation and only used single
antiplatelet therapy.8
Conclusion:
This systematic review shows evidence that the WATCHMAN implantable LAA device may
be a suitable alternative to prevent thromboembolism in patients with NVAF who may have a
contraindication for long-term warfarin or anticoagulation use. There are numerous factors that
could affect the outcomes of patients receiving the WATCHMAN device, such as the physicians’
experience with the procedure, health status of the individual, and any history of major bleeding.
There are various risks associated with device placement, such as device related thrombus,
post-procedure related bleeding, and thromboembolic related events such as stroke. One of the
benefits of WATCHMAN is not being on lifelong anticoagulation which is the alternative in
patients currently with NVAF to reduce risk of stroke. The studies reviewed here showed
WATCHMAN was noninferior to warfarin for preventing stroke. However, we believe that more
trials showing efficacy of WATCHMAN need to be performed, especially in populations that
were not greatly represented in the studies reviewed here, including women and minority
races. There are currently two additional randomized control trials looking at the efficacy of the
WATCHMAN device in stroke risk reduction, the ASAP-TOO and the OPTION. These trials are
further researching other oral anticoagulants and their efficacy compared to WATCHMAN.
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